Drugs / P134 cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07318818 | Jan 2026 → Feb 2028 expected | IDH-wildtype glioblastoma | Tasly Pharmaceutical Group Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | P134 cells | “P134 cells are CD44/CD133 dual-targeting CAR-T cells developed by the research team led by Academician Jiang Tao and Professor Zhang Wei from the Beijing Neurosurgical...” NCT07318818 ↗ |
| Modality | Cell therapy | “P134 cells are CD44/CD133 dual-targeting CAR-T cells” NCT07318818 ↗ |
| Route | Other | “administered intratumorally or intraventricularly via an Ommaya reservoir” NCT07318818 ↗ |